Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis

Protection against Pulmonary Infection withPseudomonas aeruginosafollowing Immunization withP. aeruginosa-Pulsed Dendritic Cells

“…The host response to P. aeruginosa is a complex immunoinflammatory interaction that results in damage to the airways and lung parenchyma. Opsonizing antibodies, as well as cell-mediated immunity, seem to be associated with protective immune responses (3,5,11,17,18,20,21,28,33), although an effective vaccine for protection against chronic pulmonary colonization has not been developed. Although the present study does not define all of the mechanisms of DC-pulsed Pseudomonas induction of Pseudomonas-specific protective immunity, there is a clear demonstration of some protection of systemic administration of Pseudomonas-pulsed DC against intrapulmonary infection with P. aeruginosa.…”

“…For humans, a vaccine directed against Pseudomonas have failed to be effective, despite good antibody responses to the vaccine (21,33). Passive immunization with mucoid exopolysaccharide-specific opsonizing antibody protects against chronic P. aeruginosa infection in rats.…”

“…Investigation of the immune mechanisms leading to host resistance to bronchopulmonary infection with P. aeruginosa have focused on humoral immunity and nonspecific inflammatory responses, such as neutrophil and macrophage responses (3,11,17,20,21,28,33). For humans, a vaccine directed against Pseudomonas have failed to be effective, despite good antibody responses to the vaccine (21,33).…”

“…Bacterial virulence factors (12), as well as CF-specific host factors, may play a role in the persistence of this organism (29,35). Despite considerable effort, vaccines against P. aeruginosa infection involving conventional immunization strategies have not been efficacious (18,21,33), although recent novel approaches show some promise (14,34,36,40). The lack of progress toward the development of a vaccine against P. aeruginosa infection has been due, in part, to an incomplete understanding of the optimal P. aeruginosa antigens for the vaccine, as well as of the host immune mechanisms that mediate protective immunity against this pathogen (5,6,10).…”

Affinity Constants of Naturally Acquired and Vaccine-Induced Anti-Pseudomonas aeruginosa Antibodies in Healthy Adults and Cystic Fibrosis Patients

“…Ofcritical importance is to establish the long-term safety ofsuch vaccines and to demonstrate that immunization engenders antibodies with desired functional attributes. We have recently described the safety and immunogenicity of an octavalent O-polysaccharidetoxin A conjugate vaccine in young noncolonized CF patients [13]. In the present study we compared the affinity constants of naturally acquired and vaccine-induced anti-LPS antibodies.…”